Venetoclax, formerly known as ABT-199, is an orally administered inhibitor of BCL2 with higher selectivity for BCL2 but less activity against BCL-xL, inducing the apoptosis of CLL cells in a TP53-independent manner [24,61,62]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.